Oculis Holding AG has appointed Katie Kazem to the position of Chief Legal Officer, leveraging her extensive background in life sciences legal matters. Kazem brings over 15 years of professional experience spanning corporate law, securities regulation, and other specialized legal domains relevant to the biopharmaceutical industry.
The appointment arrives at a critical juncture for the ophthalmology-focused company, which is currently advancing three late-stage clinical programs. Privosegtor has progressed to registrational trials, while OCS-01 eye drops is expected to deliver Phase 3 clinical data in the second quarter of 2026, making robust legal and regulatory expertise essential to navigating the path toward potential commercialization.
Kazem's appointment reflects Oculis' emphasis on strengthening its leadership team during a period of significant clinical development. The addition of seasoned legal leadership typically supports companies in managing complex regulatory requirements, intellectual property considerations, and corporate governance matters inherent to late-stage drug development programs.